Corbus Pharmaceuticals Holdings (LTS:0SZI) EBIT per Share : $-7.59 (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Corbus Pharmaceuticals Holdings EBIT per Share?

Corbus Pharmaceuticals Holdings's EBIT per Share for the three months ended in Mar. 2024 was $-1.16. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-7.59.

During the past 3 years, the average EBIT per Share Growth Rate was 39.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was 26.80% per year. During the past 10 years, the average EBIT per Share Growth Rate was -21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Corbus Pharmaceuticals Holdings's EBIT per Share or its related term are showing as below:

LTS:0SZI' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -182.3 Med: -34.85 Max: 39.6
Current: 39.6

During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Corbus Pharmaceuticals Holdings was 39.60% per year. The lowest was -182.30% per year. And the median was -34.85% per year.

LTS:0SZI's 3-Year EBIT Growth Rate is ranked better than
88.12% of 1313 companies
in the Biotechnology industry
Industry Median: 3.6 vs LTS:0SZI: 39.60

Corbus Pharmaceuticals Holdings's EBIT for the three months ended in Mar. 2024 was $-9.62 Mil.

Corbus Pharmaceuticals Holdings EBIT per Share Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings EBIT per Share Chart

Corbus Pharmaceuticals Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-36.20

-47.16

-13.67

-8.35

-10.42

Corbus Pharmaceuticals Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-4.14	-1.91	-2.10	-2.42	-1.16

Corbus Pharmaceuticals Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Corbus Pharmaceuticals Holdings's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-45.077	/	4.328
=	-10.42

Corbus Pharmaceuticals Holdings's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.623	/	8.311
=	-1.16

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.59

Corbus Pharmaceuticals Holdings (LTS:0SZI) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Corbus Pharmaceuticals Holdings EBIT per Share Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Corbus Pharmaceuticals Holdings (LTS:0SZI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (LTS:0SZI) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

CRBP:USA

Address

500 River Ridge Drive, Norwood, MA, USA, 02062

Website

https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.

Corbus Pharmaceuticals Holdings (LTS:0SZI) Headlines

No Headlines